Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.
Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Role of Combination I/O in Advanced Endometrial Cancer (EC)Published: April 14th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5